QID 590903

QID 590903: Illumina Local Run Manager Multiple Vulnerabilities (ICSA-22-153-02)

AFFECTED PRODUCTS
The following devices and instruments using LRM software are affected:
Illumina In Vitro Diagnostic (IVD) devices:
NextSeq 550Dx: LRM Versions 1.3 to 3.1
MiSeq Dx: LRM Versions 1.3 to 3.1
Researcher Use Only (ROU) instruments:
NextSeq 500 Instrument: LRM Versions 1.3 to 3.1
NextSeq 550 Instrument: LRM Versions 1.3 to 3.1
MiSeq Instrument: LRM Versions 1.3 to 3.1
iSeq 100 Instrument: LRM Versions 1.3 to 3.1
MiniSeq Instrument: LRM Versions 1.3 to 3.1

QID Detection Logic (Authenticated)
QID checks for the Vulnerable version using windows registry keys

Successful exploitation of these vulnerabilities may allow an unauthenticated malicious actor to take control of the affected product remotely and take any action at the operating system level. An attacker could impact settings, configurations, software, or data on the affected product and interact through the affected product with the connected network..

CVSS V3 rated as Critical - 9.8 severity.

CVSS V2 rated as High - 7.5 severity.

Solution

Customers are advised to refer to CERT MITIGATIONS section ICSA-22-153-02 for affected packages and patching details.

Vendor References

ICSA-22-153-02 - www.us-cert.gov/ics/advisories/ICSA-22-153-02

CVEs related to QID 590903

CVE-2022-1521 | CVE-2022-1524 | CVE-2022-1519 | CVE-2022-1518 | CVE-2022-1517 |

Software Advisories

Advisory ID	Software	Component	Link
ICSA-22-153-02			www.us-cert.gov/ics/advisories/ICSA-22-153-02

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].